Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $42.60.

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a "hold" rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. HC Wainwright boosted their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, September 5th. Truist Financial boosted their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Finally, Piper Sandler restated a "neutral" rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of the company's stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. This represents a 13.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. The trade was a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. Gladius Capital Management LP purchased a new stake in Collegium Pharmaceutical during the second quarter valued at about $32,000. nVerses Capital LLC boosted its stake in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock worth $55,000 after purchasing an additional 1,600 shares during the period. GAMMA Investing LLC grew its position in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock worth $55,000 after purchasing an additional 792 shares in the last quarter. CWM LLC lifted its holdings in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock valued at $58,000 after purchasing an additional 736 shares in the last quarter. Finally, TD Private Client Wealth LLC boosted its position in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after buying an additional 483 shares during the period.

Collegium Pharmaceutical Stock Performance

Shares of COLL traded down $0.45 during mid-day trading on Friday, hitting $29.96. The stock had a trading volume of 394,164 shares, compared to its average volume of 475,022. The company has a market cap of $966.21 million, a PE ratio of 12.91 and a beta of 0.95. The company's fifty day simple moving average is $35.69 and its two-hundred day simple moving average is $34.75. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a fifty-two week low of $25.16 and a fifty-two week high of $42.29.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.